iTolerance

Executive Summary

iTolerance is a preclinical-stage regenerative medicine company developing first-in-class technologies to enable tissue, organoid, or cell therapy without the need for lifelong immunosuppression. Leveraging a proprietary data-driven platform, the company is advancing a pipeline of product candidates, including iTOL-200, iTOL-201, and iTOL-401, aimed at curing various diseases by inducing immune tolerance. Founded in 2020 and headquartered in Miami, Florida, iTolerance operates at the intersection of cell and gene therapy, focusing on addressing the critical challenge of immune rejection in transplanted cells and tissues. The company's approach has the potential to transform the treatment landscape for conditions such as type 1 diabetes, liver diseases, and other disorders requiring cell replacement therapies. As a privately held, pre-clinical entity, iTolerance has not yet disclosed total funding or valuation. The company's technologies are still in the early stages of development, with no clinical data reported to date. iTolerance's success hinges on demonstrating proof-of-concept in preclinical models and advancing its candidates toward IND-enabling studies. The company faces significant technical and regulatory hurdles typical of early-stage biotech ventures, but its novel approach to immune tolerance could address a major unmet need in regenerative medicine. Key upcoming milestones include preclinical efficacy data, manufacturing process development, and potential partnership discussions to support future clinical trials.

Upcoming Catalysts (preview)

• Q4 2026IND Enabling Studies for iTOL-20035% success
• Q2 2027Preclinical Proof-of-Concept Data for iTOL-20130% success
• TBDStrategic Partnership or Licensing Deal25% success